Better prognosis for children born with severe acute asphyxia
“Previously, we went by the EEG pattern when the baby was six hours old, which sometimes meant interrupting life-sustaining interventions,” says Boubou Hallberg, paediatrician and researcher at the Department of Clinical Sciences, Intervention and Technology (CLINTEC), Karolinska Institutet. “Now we know that the values can be normalised for up to 48 hours with brain cooling treatment, greatly reducing the risk of serious damage.”
Boubou Hallberg is a clinician at the neonatal intensive care unit at Karolinska University Hospital, Huddinge. The research he presents in his doctoral thesis forms much of the basis of the recent changes in the way babies born with acute hypoxia are treated, and one of Europe’s most modern unit for neonatal intensive care is now being built in Huddinge. But his findings have also been of major significance in other countries.
Babies who are brain damaged on account of asphyxia often develop motor disabilities, such as cerebral palsy (CP). Boubou Hallberg shows in his thesis that surprisingly many, including those who have no motor deficiencies, also develop cognitive problems, such as ADHD, language disorders and difficulties processing impressions.
“The child must therefore be monitored until at least the age of six,” he says. “They might need supportive training and special needs teachers when they start school.”
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.